What to do if you are resistant to Panitumumab

Panitumumab is used to treat a type of colon or rectal cancer that has spread to other parts of the body during or after treatment with other chemotherapy drugs. Panitumumab belongs to a class of drugs called monoclonal antibodies, which work by slowing or stopping the growth of cancer cells. Resistance to panitumumab is associated with specificRAS mutations. RAS is an oncogene family, including KRAS and NRAS genes.

When mutated, these genes can transform normal cells into cancer cells by providing the cells with a constant stimulus for growth. KRAS mutations are particularly common and can be detected in 40% of metastatic colorectal tumors. KRAS mutations often lead to constitutive activation of EGFR and are associated with resistance to anti-EGFR drugs such as panitumumab. Doctors may combine panitumumab with other drugs to enhance the effectiveness of treatment. For example, combining it with chemotherapy drugs (such as fluorouracil) or other targeted drugs (such as cetuximab) can increase the chance of inhibiting tumor growth. Combination therapy may attack tumor cells through multiple pathways and reduce the development of drug resistance. However, everyone’s physique is different and their resistance to drugs is also different. If you feel unwell, please inform your doctor in time.

It is understood that the original version of panitumumab has not yet been launched in China, and therefore it has not been covered by medical insurance. The price of the Hong Kong original version of panitumumab sold in Hong Kong, China100mg/5mL may be around RMB 9,000 (the price may fluctuate due to exchange rates). There are currently no generic drugs of Panitumumab on the market. If a patient has a need to purchase Panitumumab, please consult a medical consultant for specific prices and more drug information.